Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oleclumab +/- Durvalumab + Chemo in Metastatic Pancreatic Cancer
NCT03611556Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jun 2018
- Primary completion
- Jul 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of oleclumab in pancreatic ductal adenocarcinoma (PDAC) (7 arms), sponsored by MedImmune. Primary endpoints: Treatment-emergent Adverse Events, Dose-limiting Toxicities and 1 more. Started Jun 2018; status: completed.
02
Drugs
oleclumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03611556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03611556.